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ORIGINAL INVESTIGATION
-Blockers May Reduce Mortality and
Risk of Exacerbations in Patients With
Chronic Obstructive Pulmonary Disease
Frans H. Rutten, MD, PhD; Nicolaas P. A. Zuithoff, MSc; Eelko Hak, MSc, PhD;
Diederick E. Grobbee, MD, PhD; Arno W. Hoes, MD, PhD
Background: Physicians avoid the use of -blockers in
patients with chronic obstructive pulmonary disease
(COPD) and concurrent cardiovascular disease because
of concerns about adverse pulmonary effects. We as-
sessed the long-term effect of -blocker use on survival
and exacerbations in patients with COPD.
Methods:An observational cohort study using data from
the electronic medical records of 23 general practices in
the Netherlands. The data included standardized infor-
mation about daily patient contacts, diagnoses, and drug
prescriptions.
Results: In total, the study included 2230 patients 45
years and older with an incident or prevalent diagnosis
of COPD between 1996 and 2006. The mean (SD) age
of the patients with COPD was 64.8 (11.2) years at the
start of the study, and 53%of the patients weremale. Dur-
ing a mean (SD) follow-up of 7.2 (2.8) years, 686 pa-
tients (30.8%) died and 1055 (47.3%) had at least 1 ex-
acerbation ofCOPD.The crude and adjusted hazard ratios
with Cox regression analysis of -blocker use for mor-
tality were 0.70 (95% confidence interval [CI], 0.59-
0.84) and 0.68 (95% CI, 0.56-0.83), respectively. The
crude and adjustedhazard ratios for exacerbationofCOPD
were 0.73 (95% CI, 0.63-0.83) and 0.71 (95% CI, 0.60-
0.83), respectively. The adjusted hazard ratios with the
propensity score methods were even lower. Subgroup
analyses revealed that patients with COPD but without
overt cardiovascular disease had similar results.
Conclusion: Treatment with -blockers may reduce the
risk of exacerbations and improve survival in patientswith
COPD, possibly as a result of dual cardiopulmonary pro-
tective properties.
Arch Intern Med. 2010;170(10):880-887
C HRONIC OBSTRUCTIVE PUL-monary disease (COPD) isa common disease with amarked negative impacton quality of life as well as
high hospitalization andmortality rates.1 It
is expected to become the thirdmost com-
mon cause of death in the Western world
by the year 2020.2 Routinely used thera-
pies in COPD focus on bronchial obstruc-
tion and do not or only marginally modify
mortality risk.1,3BecauseCOPDisalsochar-
acterizedby systemic inflammation,1 other
treatment optionswould be possible. Sys-
temic inflammation in COPD promotes
atherosclerotic disease progression4 inde-
pendent of age, smoking, or other cardio-
vascular risk factors.5 Also, tobacco smok-
ing is a major cause of COPD as well as of
atherosclerosis. Therefore, patients with
COPD are prone to develop cardiovascu-
lar diseases,which account formost deaths
in these patients.4,5
It has recently been emphasized that the
differential diagnosis between chronic pul-
monary and heart disease is difficult.6 Is-
chemicheart disease andheart failure could
be asymptomatic in patients with COPD
whenbreathlessness, fatigue, andevenchest
pain on exertion are misinterpreted as
COPD-related symptoms.6 Indeed, recent
studies showed high prevalence rates of
heart failure in elderly patientswithCOPD,
with most cases being unrecognized.7,8
Therapywith cardiovascular drugs, no-
tably -blockers, is known to improve the
survival of patients within a large spec-
trum of cardiovascular diseases, including
ischemic heart disease and heart fail-
ure.9,10 -Blockers could theoretically also
exert beneficial effects in patients with
COPD by tempering the sympathetic ner-
vous system or by reducing the ischemic
burden.11Meta-analyseshavealreadyshown
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erated by patients with COPD,12 even thosewith some re-
versibility(asthmaticcomponent).13 InpatientswithCOPD,
single-dose or long-term treatmentwith cardioselective-
blockersdidnothaveasignificanteffectonforcedexpiratory
volume in 1 second (FEV1), 2-agonist response, inhaler
use, or respiratory symptoms.12 In patients with reactive
airway disease, the use of cardioselective -blockers was
associatedwitha small decrease inFEV1 anda similar small
increase in -agonist response with the first dose, both of
which normalized with continued treatment.13,14 The tra-
ditional dogma, however, states that -blockers are
contraindicated inCOPDbecauseof their presumedbron-
choconstrictive properties and “competition” with 2-
agonists15; therefore, many physicians avoid prescribing
-blockers in patients with COPD.16
There is evidence about themortality-reducing poten-
tial of -blocker use in certain subpopulations of patients
withCOPDand cardiovascular disease, ie, in patients post–
myocardial infarction and in those undergoingmajor vas-
cular surgery.17,18 However, there is no clear evidence that
-blocker use increases the survival of patientswithCOPD
without (overt) cardiovascular comorbidities.Only a single
study showed that treatment with -blockers had a non-
significant tendency to reduce all-cause mortality in pa-
tientswithCOPDandhypertension.19We thereforewanted
to assess whether long-term -blocker use improves sur-
vival and reduces the risk of exacerbations in patientswith




This cohort study was performed within the framework of the
Utrecht General Practitioners (GPs) Network database, a net-
work consisting of 35 collaborating GPs working in 23 prac-
tices in the vicinity of Utrecht, the Netherlands. Since 1992,
GPs electronically enter all data related to daily patient con-
tacts into a GP information system.20 The information, which
includes disease status, reasons for encounter, specialist let-
ters, and medical prescriptions, is available for all patient en-
counters.20 All diagnoses and drug prescriptions are coded ac-
cording to the International Classification of PrimaryCare, Second
Edition (ICPC-2), and theAnatomical Therapeutic Chemical Clas-
sification standard, respectively.21 In December 2005, the net-
work included approximately 60 000 patients, 20 362 of whom
were 45 years or older.
The present study included all patients 45 years or olderwith
an incident or prevalent diagnosis of COPD (ICPC-2 code R91
[chronic bronchitis] or R95 [COPD or emphysema]) between
January 1, 1995, andDecember, 31, 2005. The ICPC-2 codes are
based on symptoms (dyspnea, cough, or sputumproduction for
at least 3months a year for 2 consecutive years) and pulmonary
rhonchi during these episodes and, in case of R95, preferablywith
spirometric evidence of pulmonary obstruction.21 From a pre-
vious study, we know that in approximately 70% of cases the
diagnosis of COPD conforms to theGOLD (Global Initiative for
Chronic Obstructive Lung Disease) criteria.22
All-causemortality and the first exacerbation ofCOPDwithin
the study time frame were the outcomes of the study. Eligible
patients were followed up until they died (study end point) or
moved or until the end of the study period (December 31, 2005),
whichever came first. Patients who experienced exacerbations
ofCOPD remained eligible for the study outcomeof death. Those
who moved and thus left the care of the GP connected with
the network during the study period were censored and con-
tributed no person time or events beyond that time. An exac-
erbation of COPD was defined as a pulsed-dose prescription
of prednisone or prednisolone during 7 to 10 days and/or a hos-
pital admission for an exacerbation. The study was conducted
in accordance with the Law for the Protection of Personal Data
(in Dutch:Wet Bescherming Persoonsgegevens) and conformed
to the Declaration of Helsinki.
DATA ANALYSIS
Cox proportional (CP) hazards regression analyses were used
to calculate crude (unadjusted) and adjusted hazard ratios
(HRs) and their 95% confidence intervals (CIs) for the risk of
all-cause death and COPD exacerbation associated with the
use of -blockers as well as separately for selective and non-
selective -blockers. Adjusted HRs were calculated after cor-
rection for the following (potentially confounding) variables:
age, sex, current and former smoking, history of cardiovascu-
lar disease (ie, angina pectoris, myocardial infarction, coro-
nary artery bypass grafting, percutaneous coronary interven-
tion, atrial fibrillation, heart failure, peripheral arterial
disease, or stroke), hypertension, diabetes mellitus, cardio-
vascular drug use other than -blockers, pulmonary drug use,
and referral to a pulmonologist.
Also, a propensity score (PS) techniquewas used as amethod
to balance covariates associated with -blocker use between
groups.23 The PS was calculated as a continuous variable and
was derived from a logistic regression model, with -blocker
use as the dichotomous dependent variable and the following
covariates known from the literature to be associated with -
blocker prescription as independent variables: history of hy-
pertension, angina pectoris, myocardial infarction, coronary ar-
tery bypass grafting, percutaneous coronary intervention, atrial
fibrillation, or heart failure. The adjusted HRs of -blocker use
were then calculated by including the continuous PS as the only
covariate in the Cox analysis.23 The logistic model to record
the continuous PS with -blocker use as the dichotomous de-
pendent variable had an area under the receiver operating char-
acteristic curve of 0.77 (95%CI, 0.75-0.80), indicating that the
model adequately predicted -blocker use.
To address the possibility of (residual) confounding by in-
dication,weperformedsubgroupanalyses, includingpatientswith
COPD but without overt cardiovascular disease, ie, without an-
gina pectoris,myocardial infarction, coronary artery bypass graft-
ing, percutaneous coronary intervention, atrial fibrillation, heart
failure, peripheral arterial disease, stroke, or diabetes, thus leav-
ing hypertension as the main remaining indication for the pre-
scription of -blockers. Other subgroups that we studied sepa-
rately consisted of patients with COPD (1) who used 2 or more
pulmonary drugs, (2) who inhaled -agonists, (3) who inhaled
anticholinergic agents, and (4)whowere referred to apulmonolo-
gist; a fifth group comprised incident cases of COPD.
Because only 44 patients (2.0%)used a-blocker as the single
cardiovascular agent, we did not perform a separate analysis
of this subgroup of patients. Interestingly, these 44 patients had
much lower event rates than other subgroups. Only 3 patients
(6.8%) died, and 6 (13.6%) had 1 or more exacerbations of
COPD. Smoking status was missing in 34.1% of patients. As
the exclusion of patients with a missing value (so-called com-
plete case analysis)may lead to biased results and loss of power,
we imputed missing values for smoking status by using a re-
gression method with the addition of a random error term.24
Imputation was based on the correlation between this missing
variable and all other variables. As a check, we performed a sepa-
rate reanalysis that was restricted to “full cases,” ie, without
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imputation of missing smoking status, with similar results on
the Cox regression analyses, although with broader CIs, as a
result. As a second check, we performed sensitivity analyses
in which all patients with missing smoking status were de-
fined first as smokers (former and current) and second as non-
smokers, again showing similar results on the Cox regression
analyses. All analyses were performed using SPSSWindows ver-
sion 15.0 (SPSS Inc, Chicago, Illinois).
RESULTS
A total of 2230 patients 45 years and older with a diag-
nosis of COPD were included in the study. Of the 2230
patients, 560 (25%) had prevalent COPD at the start of
the study and 1670 (75%) developed COPD during the
follow-up period (incident COPD). The mean (SD) age
of the patients at the start of the study period was 64.8
(11.2) years, and 53% of the patients were male. In total,
686 patients (30.8%) died: 27.2% of those who used a
-blocker comparedwith 32.3% of those who did not use
a -blocker (P=.02). One thousand fifty-five patients
(47.3%) had at least 1 exacerbation of COPD during the
mean (SD) follow-up period of 7.2 (2.8) years: 42.7% of
those who used a -blocker and 49.3% of those who did
not use a -blocker (P=.005). Patient characteristics ac-
cording to -blocker use are presented in Table 1. In
total, 44.9% of the patients with COPD had cardiovas-
Table 1. Characteristics of 2230 Patients 45 Years or Older With a Diagnosis of Chronic Obstructive Pulmonary Disease










Age, mean (SD), ya 64.8 (11.2) 64.7 (10.3) 64.8 (10.3) .87
Male sex 1183 (53.0) 331 (49.8) 852 (54.4) .04
Referral to a pulmonologist 575 (25.8) 151 (22.7) 424 (27.1) .03
Current smokersb 545 (37.1) 166 (34.6) 379 (38.3) .16
Former smokersb 723 (49.2) 245 (51.0) 478 (48.3) .33
Never smokersb 201 (13.7) 69 (14.4) 132 (13.3) .59
Cardiovascular risk factors
Hypertension 875 (39.2) 444 (66.8) 431 (27.5) .001
Diabetes 372 (16.7) 160 (24.1) 212 (13.5) .001
Cardiovascular diseases
Angina pectoris 363 (16.3) 217 (32.6) 146 (9.3) .001
Myocardial infarction 104 (4.7) 64 (9.6) 40 (2.6) .001
Ischemic heart diseasec 439 (19.7) 255 (38.3) 184 (11.8) .001
Atrial fibrillation 222 (10.0) 125 (18.8) 97 (6.2) .001
Heart failure 546 (24.5) 213 (32.0) 333 (21.3) .001
Stroke 155 (7.0) 60 (9.0) 95 (6.1) .01
Peripheral arterial disease 162 (7.3) 75 (11.3) 87 (5.6) .001
Cardiovascular drug use
-Blockers 665 (29.8) NA NA NA
Cardioselective NA 545 (24.4) NA NA
Nonselective NA 193 (8.7) NA NA
Angiotensin-converting enzyme inhibitors 667 (29.9) 331 (49.8) 336 (21.5) .001
Angiotensin receptor blockers 191 (8.6) 110 (16.5) 81 (5.2) .001
Aldosterone antagonistsd 188 (8.4) 83 (12.5) 105 (6.7) .001
Acetylsalicylic acid or clopidogrel 374 (16.8) 198 (29.8) 176 (11.2) .001
Statins 393 (17.6) 222 (33.4) 171 (10.9) .001
Thiazide diuretics 413 (18.5) 209 (31.4) 203 (13.0) .001
Loop diuretics 850 (38.1) 325 (48.9) 525 (33.5) .001
Nitrates 457 (20.5) 246 (37.0) 211 (13.5) .001
Calcium channel blockers 421 (18.9) 227 (34.1) 194 (12.4) .001
Digoxin 244 (10.9) 107 (16.1) 137 (8.8) .001
Vitamin K antagonists 437 (19.6) 208 (31.3) 229 (14.6) .001
Pulmonary drug use
Inhaled 2-sympathicomimetics 1288 (57.8) 349 (52.5) 939 (60.0) .001
Short-acting 1056 (47.4) 277 (41.7) 779 (49.8) .001
Long-acting 621 (27.8) 162 (24.4) 459 (29.3) .02
Anticholinergic inhalers 1357 (60.9) 432 (65.0) 925 (59.1) .01
Inhalation corticosteroids 1354 (60.7) 399 (60.0) 955 (61.0) .65
Xanthine derivates 154 (6.9) 32 (4.8) 122 (7.8) .01
Abbreviation: NA, not applicable.
aAt study entry.
bPercentages were calculated for 1469 participants because smoking status was missing in 761 persons (34.1%).
c Ischemic heart disease is a composite variable consisting of patients with angina pectoris, prior myocardial infarction, coronary artery bypass grafting, or
percutaneous coronary intervention.
dAldosterone antagonists are spironolactone and eplerenone.
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cular comorbidities. The number of patients with either
cardiovascular disease or hypertension or diabetes was
even higher (66.3%). This last group had significantly
higher mortality rates than those without these diseases
or cardiovascular risk factors (35.5% vs 21.4%; P .001).
As a consequence of these comorbidities, the number of
cardiovascular drug prescriptions was high. As many as
665 patients (29.8%)were prescribed-blockers, mainly
cardioselective ones (24.4%).Kaplan-Meier curves showed
that patients who used -blockers had a higher survival
rate than nonusers (Figure1), while patients withCOPD
who were referred to a pulmonologist had a lower sur-
vival rate than those who were not referred during the
follow-up period (Figure 2).
ALL-CAUSE MORTALITY
The crude and adjusted HRs based on the multivariable
CP hazard model for -blocker use were 0.70 (95% CI,
0.59-0.84) and 0.68 (95%CI, 0.56-0.83), respectively. The
adjustedHRconditional on the PSwas 0.64 (95%CI, 0.52-
0.77). For cardioselective-blockers, the adjustedHRs (CP
and PS) were 0.67 (95%CI, 0.55-0.83) and 0.63 (95%CI,
0.51-0.77). For nonselective-blockers, the adjustedHRs
(CP andPS)were 0.82 (95%CI, 0.61-1.10) and 0.80 (95%
CI, 0.60-1.05), respectively (Table 2).
ALL-CAUSE MORTALITY IN SUBGROUPS
In the subgroup of patients without overt cardiovascu-
lar disease (n=1229), 239 patients (19.4%) used -
blockers, and in total 241patients (19.6%)died. The crude
HR and the adjusted HRs (CP and PS) for any -blocker
use in this subgroupwere 0.60 (95%CI, 0.41-0.87), 0.67
(95% CI, 0.45-0.99), and 0.68 (95% CI, 0.46-1.02), re-
spectively (Table 3).
Other subgroup analyses showed similar results, with
the exception of patients referred to the pulmonologist
(Table 3). This last subgroup showed a lower and non-






















Figure 1. Cumulative survival of patients with chronic obstructive pulmonary






















Figure 2. Cumulative survival of patients with chronic obstructive pulmonary
disease according to referral to a pulmonologist.
Table 2. Crude and Adjusted Hazard Ratios (HRs) for Mortality According to -Blocker Use in 2230 Patients With a Diagnosis
of Chronic Obstructive Pulmonary Diseasea
Variable







Unadjusted (crude) 0.70 (0.59-0.84) 0.69 (0.57-0.83) 0.80 (0.61-1.06)
Covariates included in the Cox model to calculate adjusted HRs 
Age 0.66 (0.56-0.79) 0.64 (0.54-0.78) 0.80 (0.61-1.05)
Sex 0.69 (0.58-0.82) 0.66 (0.55-0.80) 0.84 (0.63-1.11)
Current or former smoker 0.69 (0.58-0.81) 0.66 (0.55-0.79) 0.83 (0.63-1.10)
Diabetes, hypertension, cardiovascular diseases 0.65 (0.54-0.79) 0.64 (0.52-0.79) 0.77 (0.57-1.03)
Cardiovascular drugs other than -blocker 0.67 (0.55-0.81) 0.64 (0.52-0.79) 0.82 (0.61-1.10)
Pulmonary drugs 0.67 (0.55-0.82) 0.65 (0.53-0.80) 0.82 (0.61-1.10)
Referral to a pulmonologist 0.68 (0.56-0.83) 0.67 (0.55-0.83) 0.82 (0.61-1.10)
Adjusted with propensity scoreb 0.64 (0.52-0.77) 0.63 (0.51-0.77) 0.80 (0.60-1.05)
aAdjusted HRs based on the Cox proportional hazards model were calculated step by step after adjustment for age, sex, current or former smoking, diabetes,
hypertension, cardiovascular diseases, cardiovascular drugs other than the one under study, use of pulmonary inhalation drugs, and referral to a pulmonologist.
Cardiovascular drugs include -blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, aldosterone antagonists, digoxin, loop and
thiazide diuretics, nitrates, aspirin, vitamin K antagonists, and calcium channel blockers. Pulmonary drugs include inhalers of 2-agonists, anticholinergic agents,
corticosteroids, and oral xanthine derivates.
bAdjusted HRs of -blocker use are conditional on the propensity score (based on covariates related to prescription of -blockers).
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justedHRs (CP andPS) for any-blocker use of 0.80 (95%
CI, 0.59-1.08), 0.72 (95%CI, 0.51-1.03), and 0.81 (95%
CI, 0.58-1.13), respectively (Table 3).
Of the 1670 patients with incident COPD, 530 used a
-blocker: 191 patients already used-blockers and con-
tinued the use after the diagnosis; 84 patients stopped
using -blockers at the time of diagnosis; and 255 pa-
tients started -blocker use after the diagnosis of COPD.
Separate analyses of these 3 subgroups of patients with
incident COPD showed that those who discontinued -
blocker use had the highest HRs formortality, with crude
and adjusted HRs (CP and PS) of 0.71 (95% CI, 0.46-
1.11), 0.89 (95%CI, 0.56-1.42), and 0.75 (95%CI, 0.47-
1.19), respectively.
EXACERBATIONS OF COPD NECESSITATING
PULSED-DOSE PREDNISONE OR PREDNISOLONE
The adjusted HRs (CP and PS) of an exacerbation for any
-blocker use were 0.71 (95% CI, 0.60-0.83) and 0.64
(95%CI, 0.55-0.75), respectively, whichwere in the same
range of the effect seen on survival (Table 4). Cardio-
selective and nonselective -blockers did not substan-
tially differ in their effects.
EXACERBATIONS OF COPD IN SUBGROUPS
In the subgroup of patients without overt cardiovascu-
lar disease, 42.3% experienced at least 1 exacerbation of
COPD during the follow-up. The crude HR and ad-
justedHRs (CP and PS) for any-blocker use in this sub-
groupwere 0.66 (95%CI, 0.53-0.84), 0.66 (95%CI, 0.52-
0.86), and 0.68 (95% CI, 0.46-1.02), respectively
(Table 5). Other subgroup analyses showed similar re-
sults, including the subgroup of patients who were re-
ferred to a pulmonologist (Table 5).
COMMENT
To our knowledge, this is the first observational study that
shows that long-term treatment with -blockers may im-
prove survival and reduce the risk of an exacerbation of
COPD in the broad spectrum of patients with a diagnosis
of COPD, including those who have COPD with but, im-
portantly, also without overt cardiovascular comorbidi-
ties. Cardioselective -blockers have larger beneficial ef-
fects onmortality thannonselective ones but similar effects
on the risk of exacerbation of COPD.Whether-blockers
can also cause beneficial pulmonary activity and therefore
are truly “cardiopulmonary” drugs remains to be proved.
Patientswithout (overt) cardiovascular comorbidities inour
study still hadhypertension as the reason for-blocker use,
and -blockers are well known to reduce cardiovascular
mortality in the treatment of hypertension. Importantly,
however, the reduction in risk of exacerbation of COPD
by -blockers cannot easily be explained by cardiovascu-
lar effects alone. The association with survival also re-
mained in the very small group of 44 patients who used
-blockers as single-agent cardiovascular therapy, suggest-
ing that -blockers offer a class-specific effect, indepen-
dent of other cardiovascular drugs.
Previous observational studies in patientswithCOPD
have already shown the beneficial effects of angiotensin-
converting enzyme inhibitors and angiotensin receptor
blockers and statins on all-cause mortality.25,26 We were
unable to reproduce thesebeneficial effects forangiotensin-
converting enzyme inhibitors or angiotensin receptor
blockers in our study (adjusted Cox HR, 1.01; 95% CI,
0.84-1.21). For statins, we could detect a nonsignificant
beneficial trend for survival (adjustedCoxHR, 0.83; 95%
CI, 0.65-1.08) (data not shown). An observational study
with -blockers as single-agent therapy in patients with
hypertension and (partly self-reported) COPD showed
that -blockers had a tendency to reduce all-cause mor-
tality compared with other cardiovascular drugs.19 Im-
portantly, in this last study, calciumchannel blockers and
diuretics did not have mortality-reducing capacities in
these patients with COPD.19,26 Recently, a small retro-
spective observational study suggested that patientswho
were using -blockers at the time of hospitalization for
anacute exacerbationofCOPDhad lower in-hospitalmor-
tality.27 Also, in this last study, calcium channel block-
ers did not prove to have mortality-reducing capacities.
Table 3. Crude and Adjusted Hazard Ratios (HRs)
for Mortality According to -Blocker Use in Subgroups





No overt cardiovascular disease (n=1229);
241(19.6%) died
Any -blocker (n=239)
Unadjusted (crude) 0.60 (0.41-0.87)
Adjusted with Coxa 0.67 (0.45-0.99)
Adjusted with propensity scoreb 0.68 (0.46-1.02)
Patients who used 2 or more pulmonary drugs
(n=1419); 442 (31.1%) died
Any -blocker (n=417)
Unadjusted (crude) 0.66 (0.53-0.82)
Adjusted with Coxa 0.62 (0.48-0.80)
Adjusted with propensity scoreb 0.60 (0.49-0.74)
Patients who used 2-sympathicomimetics
(n=1288); 384 (29.8%) died
Any -blocker (n=349)
Unadjusted (crude) 0.66 (0.52-0.83)
Adjusted with Coxa 0.64 (0.49-0.85)
Adjusted with propensity scoreb 0.60 (0.46-0.79)
Patients who inhaled anticholinergic agents
(n=1357); 463 (34.1%) died
Any -blocker (n=432)
Unadjusted (crude) 0.68 (0.56-0.84)
Adjusted with Coxa 0.68 (0.53-0.87)
Adjusted with propensity scoreb 0.60 (0.48-0.76)
Incident cases of COPD (n=1670);
472 (28.3%) died
Any -blocker (n=530)
Unadjusted (crude) 0.73 (0.59-0.89)
Adjusted with Coxa 0.73 (0.57-0.92)
Adjusted with propensity scoreb 0.63 (0.50-0.79)
Patients who were referred to a pulmonologist
(n=575); 233 (40.5%) died
Any -blocker (n=151)
Unadjusted (crude) 0.80 (0.59-1.08)
Adjusted with Coxa 0.72 (0.51-1.03)
Adjusted with propensity scoreb 0.81 (0.58-1.13)
aAdjusted Cox HRs of -blocker use were calculated step by step after
adjustment for age, sex, current or former smoking, cardiovascular risk factors,
cardiovascular diseases, cardiovascular drugs other than the one under study,
use of pulmonary inhalation drugs, and referral to a pulmonologist.
bAdjusted HRs of -blocker use are conditional on the propensity score
(based on covariates related to prescription of -blockers).
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In our study, however, calcium channel blockers had a
significant beneficial effect on all-cause mortality, with
an adjusted Cox HR of 0.77 (95% CI, 0.62-0.96), while
diuretics had an adjusted CoxHR of 1.27 (95%CI, 1.04-
1.57) (data not shown).
The beneficial effects of the use of multiple cardio-
vascular drugs in patients with COPD suggests that treat-
ment of (concealed) concurrent cardiovascular disease
could play a role.26 Previous studies have shown that the
beneficial effect of -blockade on mortality among pa-
tients after myocardial infarction was similar for those
with and without COPD and that the use of -blockers
improved survival in patients with COPD who had con-
current hypertension or signs of atherosclerosis.18,19 These
results, and the fact that our study showed thatmore than
half of the patients with COPD had cardiovascular risk
factors or overt cardiovascular diseases, similar to pre-
vious studies,8,25 should urge physicians to be alert to de-
tect (early stages of) cardiovascular diseases in these pa-
tients. In every patient with COPD, history taking should
include questions about chest discomfort that is sugges-
tive of angina pectoris, and physical examination should
include an investigation of the heart and measurements
of blood pressure and pulse rate. In case of doubt, we rec-
ommend additional investigations such as B-type natri-
uretic peptide measurements, (exercise) electrocardiog-
raphy, and, if the results of one of these tests are abnormal,
echocardiography.22 Interestingly, the association of -
blocker use with all-cause mortality and risk of exacer-
bation of COPD also remained in patients who were tak-
ing 2 ormore pulmonary drugs orwhowere using inhaled
2 sympathicomimetics or anticholinergic agents. There-
fore, inhaled pulmonary medication seems not to inter-
fere with the results of -blocker use.
-Blockers are known to temper the sympathetic ner-
vous system, including the reductionof theheart rate; there-
fore, the negative systemic effects in the disease progres-
sion of COPD could be diminished.11 Clinical trial data
already suggest that heart rate reduction itself is an im-
portantmechanism of the benefit of-blockers, and large
epidemiological studies have shown that resting heart rate
was an independent predictor of all-causemortality in in-
dividuals with and without cardiovascular disease.28
The beneficial effects of -blocker use on the sur-
vival in patients who use inhalation of 2-sympathico-
mimetics may seem unexpected. However, animal mod-
els have already shown that -blockers can upregulate
2-receptors in the lung and thus even improve the bron-
chodilator responsiveness and effectiveness of inhaled2-
sympathicomimetics,29 an effect that at first glance, and
at least to some physicians, seems a contraintuitive path-
way by which -blockers could exhibit beneficial ef-
fects.15 Interestingly, previous studies have also shown
that-agonists can downregulate2-receptors in asthma
and COPD.30 Moreover, there are concerns that the use
of -agonists could increase all-cause mortality.31 In our
study, the subgroup of patients who used inhaled -
agonists had similar effects of concomitant-blocker use
on mortality and risk of exacerbation of COPD as other
subgroups of patients with COPD (Table 3 and Table 5).
LIMITATIONS
In our primary care cohort, some of the patientsmay have
beenmisclassified as having COPD, and complaints such
as breathlessness and fatigue could have been caused by
concealed ischemic heart disease or heart failure,8,25 dis-
eases in which the mortality-reducing effects of -
blockers are well established.9 It is possible that we could
not completely correct for confounding by indication in
that more severely ill patients were more likely to receive
cardiovascular drugs, including -blockers. Importantly,
however, this confoundingby indicationwould lead toun-
derestimationof abeneficial treatment effect.32On thecon-
trary, “healthy user bias” does not seem to play an impor-
tant role because the effect estimates in patients without
overt cardiovascular disease were similar to those in the
total population. Another limitation of our study is that
Table 4. Crude and Adjusted Hazard Ratios (HRs) for Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)
According to -Blocker Use in 2230 Patients With a Diagnosis of COPDa
Variable






Unadjusted (crude) 0.73 (0.63-0.83) 0.75 (0.65-0.87) 0.72 (0.57-0.90)
Covariates included in the Cox model to calculate adjusted HRs 
Age 0.71 (0.62-0.82) 0.74 (0.64-0.86) 0.71 (0.56-0.89)
Sex 0.71 (0.62-0.81) 0.74 (0.64-0.85) 0.70 (0.56-0.89)
Current or former smoker 0.70 (0.61-0.80) 0.73 (0.63-0.84) 0.71 (0.56-0.89)
Diabetes, hypertension, cardiovascular diseases 0.63 (0.54-0.74) 0.68 (0.58-0.80) 0.66 (0.52-0.84)
Cardiovascular drugs other than -blocker 0.58 (0.50-0.68) 0.64 (0.54-0.75) 0.66 (0.52-0.84)
Pulmonary drugs 0.67 (0.57-0.79) 0.72 (0.61-0.85) 0.72 (0.56-0.91)
Referral to a pulmonologist 0.71 (0.60-0.83) 0.78 (0.66-0.92) 0.74 (0.58-0.94)
Adjusted with propensity scoreb 0.64 (0.55-0.75) 0.68 (0.58-0.80) 0.70 (0.56-0.89)
aAdjusted HRs based on the Cox proportional hazards model were calculated step by step after adjustment for age, sex, current or former smoking, diabetes,
hypertension, cardiovascular diseases, cardiovascular drugs other than the one under study, use of pulmonary inhalation drugs, and referral to a pulmonologist.
Cardiovascular drugs include -blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, aldosterone antagonists, digoxin, loop and
thiazide diuretics, nitrates, aspirin, vitamin K antagonists, and calcium channel blockers. Pulmonary drugs include inhalers of 2-agonists, anticholinergic agents,
corticosteroids, and oral xanthine derivates.
bAdjusted HRs of -blocker use are conditional on the propensity score (based on covariates related to prescription of -blockers).
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GPs donot always use spirometry to classify patientswith
COPD.Another studyperformedbyour group in the same
region in the Netherlands showed that 60% of the pa-
tients who are diagnosed as having COPD by their GP
(ICPC-2 code R91 or R95) indeed have COPD according
to theGOLD criteria, with a postdilatory FEV1 and forced
vital capacity ratio of less than 70%.22 However, an un-
confirmed (clinical) diagnosis of COPD is not a phenom-
enonthat is exclusively seen inprimarycare; it is evenrather
common in patientswho are being treated by pulmonolo-
gists.25,33 As alreadymentioned,misclassifiedpatientswith
COPDcouldhave concealed cardiovascular disease as the
reason for their complaints. Although this phenomenon
certainly could have played a role in our study, it is of in-
terest that -blocker use was still associated with an in-
dependent beneficial effect on mortality in those without
cardiovascular disease. Therefore, residual confounding
causedbyunobservedcovariatescannotbecompletelyruled
out.32 Importantly, the HRs of -blocker use in our study
changed in the anticipated direction in the Cox analysis
whenthedifferentconfounderswere includedoneata time.
Thismeans that potential unobserved confounders should
be stronger than the observed ones that were put in our
model to change the size of the effect, and it is unlikely
that such residual confounding exists.32
Although the smoking statuswasmissing inmanycases,
complete case analysis as well as sensitivity analysis re-
vealed that thishadno impacton the effect estimates. Smok-
ing status therefore seems not to be a confounder. More-
over, it was not related to -blocker use (Table 1).32
STRENGTHS
We included a large representative sample of patientswith
COPDwith various cardiovascular risk profiles and a long
follow-up period. In our nonrandomized study, we were
able to correct for many potential confounders, and ad-
justedHRswere similar after Cox regression analysis and
the PS method for -blocker use. Moreover, all patients
withCOPDwere included in our database, including those
who were (co-)treated by a pulmonologist, because all
individuals, except nursing residents, are registered with
a general practice in the Netherlands.
CONCLUSIONS
The results of our study suggest that the use of -block-
ers may reduce mortality as well as the risk of exacerba-
tions of COPD in a broad spectrum of patients with
COPD with concurrent hypertension or cardiovascular
disease. A meta-analysis of randomized trials has al-
ready shown that (cardioselective) -blockers are well
tolerated by patients with COPD.13 The time has come
to confirm these results in a randomized controlled
trial.
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Table 5. Crude and Adjusted Hazard Ratios (HRs)
for Exacerbations of Chronic Obstructive Pulmonary Disease
(COPD) According to -Blocker Use in Subgroups of Patients




No overt cardiovascular disease (n=1229);
520 (42.3%) with an exacerbation of
COPD
Any -blocker (n=239)
Unadjusted (crude) 0.66 (0.53-0.84)
Adjusted with Coxa 0.66 (0.52-0.86)
Adjusted with propensity scoreb 0.68 (0.46-1.02)
Patients who used 2 or more pulmonary
drugs (n=1419); 880 (62.0%) with an
exacerbation of COPD
Any -blocker (n=417)
Unadjusted (crude) 0.76 (0.65-0.88)
Adjusted with Coxa 0.72 (0.60-0.86)
Adjusted with propensity scoreb 0.69 (0.58-0.82)
Patients who used 2-sympathicomimetics
(n=1288); 805 (62.5%) with an
exacerbation of COPD
Any -blocker (n=349)
Unadjusted (crude) 0.78 (0.66-0.91)
Adjusted with Coxa 0.71 (0.59-0.86)
Adjusted with propensity scoreb 0.70 (0.59-0.84)
Patients who inhaled anticholinergic
agents (n=1357); 788 (58.1%) with an
exacerbation of COPD
Any -blocker (n=432)
Unadjusted (crude) 0.73 (0.62-0.85)
Adjusted with Coxa 0.71 (0.59-0.85)
Adjusted with propensity scoreb 0.65 (0.54-0.78)
Incident cases of COPD (n=1670);
774 (46.3%) with an exacerbation of
COPD
Any -blocker (n=530)
Unadjusted (crude) 0.77 (0.66-0.90)
Adjusted with Coxa 0.73 (0.60-0.88)
Adjusted with propensity scoreb 0.66 (0.56-0.79)
Patients who were referred to a
pulmonologist (n=575); 414 (72.0%)
with an exacerbation of COPD
Any -blocker (n=151)
Unadjusted (crude) 0.70 (0.56-0.88)
Adjusted with Coxa 0.66 (0.50-0.86)
Adjusted with propensity scoreb 0.67 (0.52-0.87)
aAdjusted Cox HRs of -blocker use, step by step after adjustment for age,
sex, current or former smoking, cardiovascular risk factors, cardiovascular
diseases, cardiovascular drugs other than the one under study, use of
pulmonary inhalation drugs, and referral to a pulmonologist.
bAdjusted HRs of -blocker use are conditional on the propensity score
(based on covariates related to prescription of -blockers).
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